Is BioAtla Inc (NASDAQ: BCAB) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Stocks Info

BCAB belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $3.39 and fluctuated between $3.8500 as its day high and $3.2600 as its day low. The current market capitalization of BioAtla Inc is $162.04M. A total of 1.2 million shares were traded on the day, compared to an average of 457.33K shares.

In the most recent transaction, MCBRINN SYLVIA bought 4,000 shares of BCAB for 2.33 per share on Dec 26 ’23. After the transaction, the Director now owns 15,125 company shares. In a previous transaction on Dec 20 ’23, SHORT JAY M PHD bought 50,000 shares at 2.14 per share. BCAB shares that Chief Executive Officer owns now total 1,439,283.

Among the insiders who bought shares, STEINMAN LAWRENCE acquired of 20,000 shares on Dec 19 ’23 at a per-share price of $2.05. This resulted in the Director holding 38,459 shares of BCAB after the transaction. In another insider transaction, Vasquez Christian bought 7,495 shares at $2.04 per share on Dec 19 ’23. Company shares held by the insider now total 115,659.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BCAB has a high of $4.07 and a low of $1.24.

As of this writing, BCAB has an earnings estimate of -$0.79 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$1. The company reported an EPS of -$0.75 in the last quarter, which was -17.20% lower than expectations of -$0.64.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BCAB’s latest balance sheet shows that the firm has $244.98M in Cash & Short Term Investments as of fiscal 2021. There were $5.37M in debt and $19.81M in liabilities at the time. Its Book Value Per Share was $1.47, while its Total Shareholder’s Equity was $210.82M.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCAB is Buy with a score of 5.00.

Most Popular

Related Posts